Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-12-19
2002-12-10
Fredman, Jeffrey (Department: 1634)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S021800, C530S324000, C530S841000, C424S085100, C523S115000, C623S011110, C623S016110
Reexamination Certificate
active
06492327
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to methods for production of transforming growth factor &bgr; (TGF-&bgr;) and, more particularly, to methods for purification of transforming growth factor &bgr; from mammalian bone tissue.
BACKGROUND OF THE INVENTION
Transforming growth factor &bgr; (TGF-&bgr;) proteins are multi-functional cytokines active in regulating growth, differentiation, and morphogenesis in a wide variety of both normal and neoplastic cell types. These growth factors share related biological activities such as chemotactic attraction of cells, promoting cell differentiation and cartilage- and bone-growth induction. TGF-&bgr; is a 25,000 MW homodimer consisting of two 12,500 subunits bound together by nine disulphide bridges. There are three potential N-linked glycosylation sites in the precursor portion of the protein, all of which appear to be used. At least five different forms of TGF-&bgr; (TGF-&bgr; 1 to TGF-&bgr; 5) have been identified and the sequence homology between the different forms of the mature TGF-&bgr; peptides range from 64-82%. The sequence homology between the precursor sequences is somewhat lower, averaging about 40%. All are functionally homologous although there is some difference in TGF-&bgr; receptor binding properties. TGF-&bgr; has been shown to be an effective cell growth promoter, particularly with epithelial cells, and the use of TGF-&bgr; as a wound healing agent has been demonstrated. It would therefore be desirable to provide methods for producing TGF-&bgr; in relatively large quantities. It would be particularly desirable to provide methods for the purification of TGF-&bgr; from mammalian tissue.
Bones include many proteins, some of which induce or promote bone growth. A great deal of research has been directed to producing specific osteoinductive proteins primarily by recombinant DNA techniques or by purification of the naturally occurring proteins. Such proteins and a variety of processes for obtaining them are the subject of numerous patents. However, very little work has been directed to the economic, large scale commercial production of the naturally occuring protein.
Collagen Corporation of Palo Alto, Calif. is the assignee of a number of patents directed to osteoinductive proteins. U.S. Pat. No. 4,434,094 by Seyedin et al., issued Feb. 28, 1984 identifies a process to partially purify an osteogenic factor and isolate a non-fibrous protein having a molecular weight less than 30 kilodaltons (kD) from demineralized bone extract using cation exchange chromatography. A partially purified bone-inducing factor of 10 to 30 kD and the purification process including extraction from demineralized bone, gel filtration, and cation exchange chromatography on a carboxymethyl cellulose column, and which may include reverse phase-high performance liquid chromatography (HPLC), is described in U.S. Pat. No. 4,627,982 by Seyedin et al., issued Dec. 9, 1986. Also by Seyedin et al., U.S. Pat. No. 4,774,228 issued Sep. 27, 1988, describes two 26 kD proteins found in bone having activity in a TGF-&bgr; assay and purified using a process similar to that taught in Seyedin's '094 patent but including reverse phase HPLC or acetic acid-urea gel electrophoresis, where the purified proteins exhibit chondrogenic activity (purportedly related to bone formation). U.S. Pat. No. 4,863,732 by Nathan et al., issued Sep. 5, 1989 is directed to an injectable solution of an osteogenic factor such as that described in Seyedin's '982 patent, combined with atelopeptide collagen and further purified by coprecipitation. Other patents relate to mixtures of atelopeptide collagen material, e.g. U.S. Pat. No. 4,789,663 by Wallace et al., issued Dec. 6, 1988 and U.S. Pat. No. 4,795,467 by Piez et al. issued Jan. 3, 1989.
U.S. Pat. No. 4,804,744 by Sen, issued Feb. 14, 1989 identifies a primary osteogenic protein (P
3
) with a molecular weight of about 22 to 24 kD. This patent also identifies proteins P
2
and P
4
which are nonosteogenic without P
3
, and further identifies a method for isolating P
3
from demineralized bone tissue including extraction, dialysis, gel filtration and HPLC steps.
U.S. Pat. Nos. 5,290,763, 5371,191 and 5,563,124 to Poser et al., Poser et al., and Damien et al. respectively describe isolation of a growth factor mixture by a multi-step procedure which preferably includes preparing the bone for extraction of proteins by grinding, cleaning, and demineralizing the bone, extracting the bone proteins, and concentrating the extracted proteins by multiple purification steps.
There is a need for a process to efficiently isolate TGF-&bgr; proteins from a natural source on a commercial scale. It would also be beneficial if such proteins could be produced in a manner designed to minimize degradation of such proteins while maximizing production. It would also be beneficial if such proteins could be produced using relatively well-known unit operations in a process which is tolerant of minor variations in process conditions.
REFERENCES:
patent: 4002602 (1977-01-01), Goldstein
patent: 4434094 (1984-02-01), Seyedin et al.
patent: 4627982 (1986-12-01), Seyedin et al.
patent: 4774228 (1988-09-01), Seyedin et al.
patent: 4789663 (1988-12-01), Wallace et al.
patent: 4795467 (1989-01-01), Piez et al.
patent: 4804744 (1989-02-01), Sen
patent: 4863732 (1989-09-01), Nathan et al.
patent: 5290763 (1994-03-01), Poser et al.
patent: 5322933 (1994-06-01), Davies et al.
patent: 5371191 (1994-12-01), Poser et al.
patent: 5563124 (1996-10-01), Damien et al.
patent: RE35694 (1997-12-01), Seyedin et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 6010698 (2000-01-01), Kussendrager et al.
Farooqui,Journal of Chromatography, 184, 335-345, 1980.
Ogawa et al.,The Journal of Biological Chemistry, 267:4, 2325-2328, 1992.
Seyedin et al.,The Journal of Biological Chemistry, 262:5, Feb. 15, 1987.
Assoian RK et al.,J Biol Chem, 258:11, 7155-60 Jun. 10, 1993.
Ogawa,Methods Enzymol, 198: 317-27, 1991.
Ogawa et al.,J Biol Chem, 267:4, 2325-8, May 5, 1992.
Roberts et al.,Biochemistry, 22:25, 5692-8, Dec. 6, 1983.
Schlunegger et al.,FEBS Lett, 303:1, 91-3, May 25, 1992.
Seyedin et al.,Proc. Natl. Acad. Sci USA, 82:8, 2267-71, Apr. 1985.
Junker Louis
Lewis Michael
Nelson Robert
Chakrabarti Arun Kr.
Fredman Jeffrey
Sulzer Biologics Inc.
LandOfFree
Isolation of purified TGF- &bgr;1 and TGF -&bgr;2 from bone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolation of purified TGF- &bgr;1 and TGF -&bgr;2 from bone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolation of purified TGF- &bgr;1 and TGF -&bgr;2 from bone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2960831